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Abstract
Background: Down syndrome is the most frequent genetic disorder in humans. Rare cases
involving partial trisomy of chromosome 21 allowed a small chromosomal region common to all
carriers, called Down Syndrome Critical Region (DSCR), to be determined. The DSCR1 gene was
identified in this region and is expressed preferentially in the brain, heart and skeletal muscle.
Recent studies have shown that DSCR1 belongs to a family of proteins that binds and inhibits
calcineurin, a serine-threonine phosphatase. The work reported on herein consisted of a study of
the subcellular location of DSCR1 and DSCR1-mutated forms by fusion with a green fluorescent
protein, using various cell lines, including human.
Results: The protein's location was preferentially nuclear, independently of the isoform, cell line
and insertion in the GFP's N- or C-terminal. A segment in the C-terminal, which is important in
the location of the protein, was identified by deletion. On the other hand, site-directed mutational
analyses have indicated the involvement of some serine and threonine residues in this event.
Conclusion: In this paper, we discuss the identification of amino acids which can be important for
subcellular location of DSCR1. The involvement of residues that are prone to phosphorylation
suggests that the location and function of DSCR1 may be regulated by kinases and/or phosphatases.
Background
Down syndrome (DS) is the genetic disease most fre-
quently afflicting humans and is detected at a ratio of one
out of every seven hundred births [1]. Although most of
those affected have an extra copy of chromosome 21, a
few more rare cases involving partial trisomy define a re-
gion common to all carriers of the syndrome, called
Down Syndrome Critical Region (DSCR), which is pur-
portedly involved with the carriers' anomalous phenotype
[2,3].
A gene located in this region, approximately 2 Mb above
D21S55, has been dubbed DSCR1 – Down Syndrome
Candidate Region 1 [4]. The genomic sequence of DSCR1
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totals 45 kb, including 7 exons and 6 introns, and analyses
of different cDNAs have found that the first four exons are
alternative and code for two isoforms of 197 amino acids
and one isoform of 171 amino acids, which differ in the
N-terminal, the last 168 residues being common [5]. Re-
cent studies have indicated the presence of an alternative
promoter region with approximately 900 bp, between ex-
ons 3 and 4, suggesting that the fourth isoform may derive
from an alternative promoter [6]. Analyses by Northern
blot have detected high levels of transcripts in brain, stri-
ated skeletal and cardiac muscles, placenta and kidney
[4,5,7–9].
Through the analysis of amino acid sequences, a high
identity has been found between DSCR1 and the human
protein ZAKI-4 [10], including a preserved region that is
supposedly a phosphatase substrate (a serine-proline rich
motif), another one assumed to be a calcineurin docking
site, and an SH3 ligand domain, involved in protein
dimerization [4,8]. ZAKI-4 is a protein whose expression
is positively activated by the thyroidal hormone triio-
dothyronine (T3); however, induction with T3 failed to
produce any significant increase in the expression of
DSCR1 [6,8,11]. Because the human proteins DSCR1 and
ZAKI-4 are capable of binding and inhibiting calcineurin
signaling in myocytes, they were grouped as members of
a new family of proteins called Myocyte-Enriched Cal-
cineurin Interacting Protein [8]. A new protein dubbed
DSCR1L2, whose gene is located in chromosome 1 and
which also presents a high identity with DSCR1 and ZAKI-
4, has also been included in this family [12]. Calcineurin,
also known as protein phosphatase 2B (PP2B), mediates
many cellular responses signalized by calcium, including
the activation of lymphocytes, neurons and muscular de-
velopment, which could be prevented by the addition of
immunosuppressive drugs or overexpression of endog-
enous inhibitor proteins, as DSCR1 [13–15]. A novel cal-
cineurin-binding protein, called CBP1, from the
pathogenic fungus Cryptococcus neoformans was recently
identified. This protein presents a serine-proline rich mo-
tif identical to DSCR1 and to other calcineurin-inhibiting
proteins and is detected in fungi to humans. Electro-
phoretic mobility experiments and mutations involving
the serines have shown that CBP1 can be a phosphopro-
tein, a substrate of calcineurin and/or of calcium-calmod-
ulin complex-dependent kinases [16].
Calcineurin, which is activated by calcium-calmodulin
signaling, regulates the nuclear import of NF-AT (Nuclear
Factor Activated T Cells) by dephosphorylation of specific
serines, promoting translocation of NF-AT to the nucleus
where, in a complex with AP1, it activates the transcrip-
tion of specific genes such as IL2 [17]. It was recently dis-
covered that the last 82 amino acid residues in the
carboxi-terminal of DSCR1 inhibit the calcineurin signal,
preventing the translocation of NF-AT to the nucleus, even
when calcineurin activity is induced by ionophore and
phorbol ester [7]. Moreover, the DSCR1 promoter region
presents a binding sequence for the NF-AT transcription
factor, indicating that DSCR1 participates in a negative
feedback-type regulation process mediated by calcineurin
itself [6,18].
In this study, we investigated the intracellular location of
DSCR1 in different cell lines and, by means of specific
mutations, we detected some possible signaling regions
within the DSCR1. Thus, we identified domains and ami-
no acids that are prone to phosphorylation/dephosphor-
ylation events that influence the protein's siting and that
may be associated with the function of the protein, which,
in turn, could be a candidate for involvement in DS
pathogenesis.
Results
All the different DSCR1 isoforms presented a preferentially 
nuclear location pattern
The DSCR1 location was detected by an analysis of the ex-
pression of the pEGFP-DSCR1 or pDSCR1-EGFP plasmids
in CHO-1, COS-7 and HEK 293 cells. The three different
DSCR1 isoforms were detected in the nucleus of the ana-
lyzed cells, with only slight signaling in the cytoplasm,
thus confirming their predominantly nuclear location. Ex-
emplary results for the third isoform are presented here
(Figs. 1,2). The other isoforms showed analogous patterns
(data not shown). The EGFP (control) displayed a homoge-
neous distribution pattern in the cells analyzed.
The 33 C-terminal residues are necessary for the nuclear 
location of the DSCR1
In an attempt to identify the region responsible for nucle-
ar targeting, expression vectors were constructed to origi-
nate truncated forms of the third DSCR1 isoform fused
with the GFP (Fig. 1). The absence of the last 33 amino ac-
ids altered the intracellular distribution of the DSCR1 and
a cytoplasmic accumulation was detected, indicating that
this region possibly contains a nuclear location signal
(Fig. 2). Sequences that were described in these 33 resi-
dues include a putative SH2 ligand domain and a cal-
cineurin docking site.
The threonines of the SH2 ligand domain and the one in 
the calcineurin docking site are both related to the DSCR1 
location
Analyses of location involving point mutations by re-
placement of threonines for alanines within these de-
scribed regions (PEYT166PI and PKIIQT160) revealed a
cytoplasmic distribution pattern of the third DSCR1 iso-
form with an accumulation of the protein in the form of
granules (Fig. 3).
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The serine-proline rich motif, identified in other proteins 
as a calcineurin substrate, is involved in subcellular loca-
tion of DSCR1
We also investigated whether the serines of the SPPASPP
motif of the fourth DSCR1 isoform (also present in the
others) could be involved in its distribution in the cell.
Point mutations involving substitution of serines by
alanines (DSCR1A108+A112) prevented the DSCR1 from
entering the nucleus and originated a distribution pattern
in the shape of small granules in the cellular cytoplasm
(Fig. 3).
Treatments with PMA/Ionomycin and Cyclosporin A
Both CHO-1 cells expressing DSCR1 mutated-forms sub-
jected to PMA/Ionomycin and/or Cyclosporin A and non-
treated cells displayed the same subcellular location
pattern (Fig. 4). In addition, small granules in the cyto-
plasm were detected in some DSCR1-mutated forms
when they were compared with nontreated cell location
patterns.
Discussion
Previous studies on the subcellular location of the DSCR1
protein have been carried out in C2C12 mouse myoblast
cell line, in which the protein was detected in the nucleus
Figure 1
Schematic DSCR1 truncation protein series (left) and subcellular location (right) Predicted domains indicated in
the diagram have been previously described [4]. Description of the different constructions is given in the material and methods
section
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[8]; thus, our analyses corroborate that finding. Our ex-
periments using fusions of DSCR1 with the green fluores-
cent protein detected the fusion protein preferentially in
the nucleus of the analyzed cells. The detection was not al-
tered by the insertion of DSCR1 in the GFP's N- or C-ter-
minal, thus precluding any kind of artifact. The location
was also independent of the cell line used and no differ-
ences were found for any of the isoforms.
Having analyzed the location of the DSCR1, our next step
was to determine the regions responsible for the protein's
location. To this end, we built truncated forms of the
DSCR1, removing regions of the C- and the N-terminal.
Using the pEGFP-DSCR1138–171 construction, we found
that the absence of the last 33 amino acids in the carboxi-
terminal altered the DSCR1's intracellular distribution,
which was now detected preferentially in the cytoplasm of
the analyzed cells. This finding was complemented by an
analysis of cells transfected with the pEGFP-DSCR11–137
plasmid, whose GFP is fused only with the 33 amino ac-
ids. An accumulation of the fusion protein in the nucleus
was detected in the cells transfected by this construction.
Hence, this region containing the 33 amino acids in the C-
terminal is required for nuclear location, suggesting that it
may act or contribute with a nuclear location signal
(NLS). However, it is important to clarify that we used the
third isoform for deletion studies because it was the first
form described and we are of the opinion that it does not
differ from the other forms insofar as subcellular location
is concerned.
The DSCR1 possesses a putative NLS in the 33 C-terminal
amino acids (RRPKPK). However, point mutations of ar-
ginines into alanines in the RRPKPK motif did not prevent
the protein's migration to the nucleus (data not shown),
suggesting that this domain either does not constitute a
NLS or that the mutations into alanines were insufficient
for its inactivation.
By means of site-directed mutagenesis, we identified ami-
no acids that are supposedly a target of phosphorylation/
dephosphorylation events and that are important for the
perfect location of DSCR1. A simple substitution of a res-
idue of threonine (DSCR1A166) for alanine resulted in cy-
toplasmic accumulation of the DSCR1. This amino acid is
contained in a probable SH2 ligand domain [4], identi-
fied in the last 33 amino acids of the protein. Based on
these results, we hypothesize that the nuclear accumula-
tion of DSCR1 can be controlled at two levels: phosphor-
ylation within a probable NLS and/or formation of a
heterodimer with a specific protein. SH2 domains partici-
pate in protein dimerization processes and can recognize
phosphorylated residues close to the tyrosine of the SH2
ligand domain [21,22]. Hence, the threonine residue in
Figure 2
Confocal laser scanning microscope images of both DSCR1 and DSCR1-mutant expression in CHO-1 (line 1,
A-D), COS-7 (line 2, E-H) and HEK 293 cells (line 3, I-L). Subcellular location of: EGFP (A, E, I), DSCR1 (pEGFP-
DSCR1)(B, F, J), DSCR11–137 (C, G, K) and DSCR1138–171 (D, H, L). The different mutational constructions are included in the
section on material and methods and analyzed in detail in the results section. Scale bars are indicated in the figure.
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the supposed SH2 ligand domain of the DSCR1, possibly
phosphorylated, may be important for its recognition,
which is assumed to be involved in controlling the pro-
tein's translocation to the nucleus.
It was recently discovered that DSCR1 interacts physically
and inhibits calcineurin signaling [6–9,11–13]. Two spe-
cific regions within the DSCR1 interact with calcineurin: a
serine-proline rich region and a region close to the car-
boxi-terminal, called "calcineurin docking site" [8]. By
point mutations in the probable calcineurin docking site
(PKIIQT), another putative signaling amino acid (threo-
nine) was identified, whose substitution by alanine pro-
voked a cytoplasmic accumulation of DSCR1. In addition,
mutants DSCR1A160 and DSCR1A166 showed an accumu-
lation of the protein in the form of granules, suggesting its
possible association with other proteins or specific struc-
tures, even of the cellular cytoskeleton.
The serine-proline rich motif of DSCR1 is highly con-
served and found from fungi to humans, acting as a sub-
strate of calcineurin [7,8,12,16,18,23]. Calcineurin acts in
the dephosphorylation of the serines inside the serine-
proline motif in the several proteins in which it is present,
differing in the number of repetitions, with three found in
NF-AT and two in DSCR1 [8,24,25]. Acting in this region,
as described for CBP1 [16], kinases and phosphatases may
be present, forming a complex. The nuclear location of the
E2F transcription factor is dependent on the formation of
a heterodimer [26], which is regulated by phosphoryla-
tion of the two serine residues that facilitate protein-pro-
tein interaction [27].
The mutant DSCR1A108+A112, in which the serine residues
of the serine-proline rich motif were substituted for
alanines, showed preferential cytoplasmic location in the
form of small points dispersed throughout the cytoplasm.
This location pattern may even be related to the accumu-
lation of DSCR1 in the cellular cytoskeleton, as described
for protein 1B associated with microtubules [28], or to
mitochondria since, in the hamster DSCR1 ortholog iso-
form adapt78, isolated from a Chinese hamster fibroblast
culture induced by oxidative stress, a probable target sig-
nal region for mitochondria was described in the N-termi-
Figure 3
Confocal laser scanning microscope images of distinct DSCR1-punctual mutants expression in CHO-1 (line 1,
A-D), COS-7 (line 2, E-H) and HEK 293 cells (line 3, I-L). Subcellular location of: DSCR1A160 (A, E, I), DSCR1A166 (B, F,
J), DSCR1A160+A166 (C, G, K) and DSCR1A108+A112 (D, H, L). The different constructions obtained by site-directed mutagene-
sis are included in the section on material and methods and analyzed in detail in the results section. Scale bars are indicated in
the figure. Mutated sequences are shown at the bottom (dots indicate the amino acids replaced by alanines).
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nal [29]. An analysis by co-visualization of this mutant
form, together with a fluorescent red reporter protein car-
rying a target sequence for mitochondria, failed to reveal
superimposition of the distribution patterns of the two
proteins (data not shown). Be that as it may, it seems clear
that the serines found in the SPPASPP motif, which may
be targets of phosphorylation/dephosphorylation events,
are important for the nuclear location and cellular activity
of the DSCR1. Recently, it was confirmed that the DSCR1
can be phosphorylated by mitogen-activated protein ki-
nase (MAPK) and glycogen synthase kinase-3 (GSK-3),
forming a substrate to calcineurin. Moreover, a specific
serine residue within the conserved SP repeat domain was
phosphorylated by GSK-3 and dephosphorylated by cal-
cineurin in vitro [30].
In addition, we carried out treatments with PMA/Ionomy-
cin, which activate calcium signaling and, inversely, with
Cyclosporin A, an immunosuppressor that blocks the in-
teraction of calcineurin with other proteins. These treat-
ments failed to change the location of the mutants
described herein, confirming that the eliminated or sub-
stituted amino acids effectively participate in a specific sig-
nal and are independent of these treatments.
By means of mutational analyses, therefore, our studies
identified amino acids that participate in the location of
the DSCR1 and that are probably responsible for a specific
cellular response. DSCR1 can represent a phosphoprotein
in which the state of phosphorylation is essential for a giv-
en location pattern and consequent activity.
Conclusions
DSCR1 has been demonstrated previously to be a nuclear
protein. In the work reported on herein, this finding has
been confirmed in different cell lines. Furthermore, we
have demonstrated the importance of the 33 C-terminal
amino acids in this location. Besides, punctual mutations
in amino acids that are prone to events of phosphoryla-
tion/dephosphorylation altered the DSCR1 location, sug-
gesting that its subcellular location and activity may be
regulated by kinases and/or phosphatases.
Methods
Plasmid constructions
The open reading frames of human DSCR1 (Genbank ac-
cession numbers U85266, U28833 and U85267) were
amplified by polymerase chain reaction [19] containing
fetal brain cDNA library (Gibco BRL) as template. Specific
forward primers, i.e., 5'-gAA gAT CTA Tgg Agg Tgg AC-3' or
5'-gAA gAT CTA Tgg Tgt ATg CCA AA-3' or 5'-gAA gAT CTA
TgC ATT TTA gAA AC-3', were used to amplify, respective-
ly, the first (exons 1,5,6,7), third (exons 3,5,6,7) and
fourth (exons 4,5,6,7) DSCR1 isoforms, according to the
nomenclature proposed in [20]. A single reverse primer,
5'-TCA gCT gAg gTg gAT cgg cgt-3', was used to amplify all
the isoforms. The amplified products with approximately
six hundred base pairs were cleaned using the Concert
PCR Purification System (Invitrogen-Life Technologies),
cut with BglII and cloned in pEGFP-C1 and pEGFP-N1
(Clontech Lab.) cut with BglII and SmaI. The stop codon
on reverse primer was eliminated for pEGFP-N1 construc-
tions. C-terminal deletions of DSCR1 (using the third iso-
form) were also carried out under standard PCR
conditions [19] using distinct reverse primers that deleted
the amino acids indicated (DSCR1148–171, DSCR1113–
171, DSCR181–171, DSCR157–171, DSCR136–171). A
single forward primer, which amplified the third isoform,
was also included in each amplification of DSCR1-mu-
tants (with BglII restriction site to facilitate the cloning
into pEGFP-C1). This isoform was used because the C-ter-
minal of DSCR1 is identical for all the isoforms and be-
cause it presents an indistinct location pattern in
comparison to the others. In addition, all the domains in-
volved in calcineurin binding are present in this isoform.
One N-terminal deletion (DSCR11–33) and two frag-
ments (DSCR1138–171, DSCR11–137) generated with
BclI restriction enzyme (Invitrogen) were also included in
this analysis. Replacement of the threonine amino acids
by alanine residues (DSCR1A160, DSCR1A166 and
DSCR1A160+A166) was done by PCR, using primers incor-
porating the desired base substitutions in the third DSCR1
Figure 4
Confocal laser scanning microscope images of
DSCR1-mutated forms after the addition of PMA/
Ionomycin and/or Cyclosporin A. Subcellular location of:
DSCR11–137 (A), DSCR1138–171 (B), DSCR1A108+A112 (C),
DSCR1A160 (D), DSCR1A166 (E) and DSCR1A160+A166 (F).
Treatments with PMA/Ionomycin and Cyclosporin A did not
influence the subcellular location patterns. Scale bars are
indicated in the figure.
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isoform. Replacement of the serine residues by alanines in
the SP motif (DSCR1A108+A112) was done similarly, but
using the fourth isoform. All the DSCR1-mutated forms
were cloned in pEGFP-C1. Details of PCR conditions and
sequence primers are available upon request. All the con-
structions were sequenced with a Big Dye Terminator Cy-
cle Sequence-ready Reaction kit and analyzed in an
automatic DNA sequence analyzer ABI-PRISM 377 (Ap-
plied Biosystems).
Cell culture and transient transfection
CHO-1 (Chinese Hamster Ovary), COS-7 (SV-40 African
Green Monkey Kidney) and HEK 293 (Human Embryonic
Kidney) cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal bovine serum,
penicillin (100 U/ml) and streptomycin (100 g/ml) in a
humidified atmosphere of 5% CO2. Cells were plated 12–
24 h prior to transfection on a 35 mm tissue culture dish
at 5  104–105 cell/dish, containing a coverslip coated
with 0.1% gelatin. The cells were transfected with Lipo-
fectamine™ 2000 (Invitrogen) and were harvested 24–48
h after transfection. The cell cultures (CHO-1) were also
subjected to treatments with PMA/Ionomycin and Cy-
closporin A (Calbiochem, CN Corp.), as described in ref-
erence [8].
Image analyses by confocal microscopy
Inverted microscopy was performed using a Zeiss LSM510
Laser-Scanning Microscope. The images were captured us-
ing 20  0.5, 40  1.2 and 63  1.4 numerical aperture ob-
jective lenses, at 488 nm (exc.) and 509 nm (em.),
corresponding to an argon ion laser with a pinhole of 73
to 103 m. All the images were color scanned.
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